Revance Therapeutics, Inc. $125 Million At-The-Market Offering

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its common stock for up to an aggregate amount of $125 million.

Based in Newark, California, Revance Therapeutics, Inc. is a biotechnology company developing neuromodulators for use in aesthetic and therapeutic indications.

The Davis Polk corporate team included partner Emily Roberts and associate Kimberly Wang. Partner Michael Farber and associate Erin van Wesenbeeck provided tax advice. Partner Pritesh P. Shah and associate Jay Frankel provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.